31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB) Download PDF Post navigationPreviousPrevious post:AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisNextNext post:Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & TherapyRelated PostsAB Science webcast – Masitinib in Sickle Cell Disease30 November 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023Revenues for the first half of 2023 and update on AB Science’s activities29 September 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023
